2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-145875
    Antibacterial agent 77 2902561-28-6 98%
    Antibacterial agent 77 (compound 12) is an antibacterial agent.
    Antibacterial agent 77
  • HY-145876
    Antibacterial agent 78 2902561-42-4 98%
    Antibacterial agent 78 (compound 30) is an antibacterial agent.
    Antibacterial agent 78
  • HY-145877
    Antibacterial agent 79 2902561-44-6 98%
    Antibacterial agent 79 (compound 32) is an antibacterial agent.
    Antibacterial agent 79
  • HY-145878
    Antibacterial agent 80 2902561-34-4 98%
    Antibacterial agent 80 (compound 20) is an antibacterial agent.
    Antibacterial agent 80
  • HY-145880
    Elongation factor P-IN-1 2906180-02-5 98%
    Elongation factor P-IN-1 is a potent inhibitor elongation factor P (EFP). Elongation factor P-IN-1 is a β-lysine derivative compound. Elongation factor P-IN-1 affects the proliferation rates of E. coli.
    Elongation factor P-IN-1
  • HY-145881
    Elongation factor P-IN-2 2906180-05-8 98%
    Elongation factor P-IN-2 is a potent inhibitor elongation factor P (EFP). Elongation factor P-IN-2 is a β-lysine derivative compound. Elongation factor P-IN-2 affects the proliferation rates of E. coli.
    Elongation factor P-IN-2
  • HY-145886
    TLR7/8 antagonist 1 2901020-63-9 98%
    TLR7/8 antagonist 1 (Compound 16c) is a competitive TLR7/8 antagonist with IC50 values of 3.91 μM and 2.19 μM, respectively. TLR7/8 antagonist 1 reduces agonist-induced production of proinflammatory cytokines, including TNFα, IFNγ and IL-1β.
    TLR7/8 antagonist 1
  • HY-14588R
    Lopinavir (Standard) 192725-17-0 98%
    Lopinavir (Standard) is the analytical standard of Lopinavir. This product is intended for research and analytical applications. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with Kis of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity. Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 14.2 μM.
    Lopinavir (Standard)
  • HY-145949
    Remdesivir de(ethylbutyl 2-aminopropanoate) 2607871-93-0 98%
    Remdesivir de(ethylbutyl 2-aminopropanoate) is an impurity of Remdesivir. Remdesivir, a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.
    Remdesivir de(ethylbutyl 2-aminopropanoate)
  • HY-145985
    CBR-3465 2225883-59-8 98%
    CBR-3465 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.16 μM against Mtb.
    CBR-3465
  • HY-145986
    CBR-6672 2225885-40-3 98%
    CBR-6672 is a mycobacterium tuberculosis (Mtb) type II NADH dehydrogenase inhibitor, with the MIC of 0.14 μM against Mtb.
    CBR-6672
  • HY-145996
    STC314 401513-39-1 98%
    STC314 is a histone-neutralizing agent. STC314 inhibits histone-mediated cytotoxicity, blocks histone-induced erythrocyte aggregation, reduces fragility, restores deformability and inhibits histone-induced aggregation and degranulation in human erythrocytes. STC314 reduces histone-mediated tissue damage, thrombocytopenia, anemia, and cell death, and improves survival in preclinical models. STC314 can be used for the research of sepsis, ischemia-reperfusion injury, and deep-vein thrombosis.
    STC314
  • HY-146003
    FAAL-IN-1 1965250-07-0 98%
    FAAL-IN-1 (compound 32) is a selective inhibitor of fatty acyl-AMP ligase (FAAL), with a Ki of 0.7 μM for FAAL28. FAAL-IN-1 shows antimycobacterial activity.
    FAAL-IN-1
  • HY-146004
    Influenza A virus-IN-4 2390067-58-8 98%
    Influenza A virus-IN-4 (compound 23b), an Oseltamivir derivative, is a potent inhibitor of neuraminidase. Influenza A virus-IN-4 exerts powerful inhibitions on influenza viruses.
    Influenza A virus-IN-4
  • HY-146009
    AL-470 2671019-15-9 98%
    AL-470 is a potent antiviral agent with EC50 values of 0.27, 0.63, and 0.35 µM against HIV-1, HIV-2, and EV-A71, respectively.
    AL-470
  • HY-146011
    HBV-IN-21 2460957-52-0 98%
    HBV-IN-21 (Compound II-8b) is an HBV DNA replication inhibitor with an IC50 of 2.2 µM. HBV-IN-21 can interact HBV 4 capsid protein with good affinity (KD = 60.0 μM).
    HBV-IN-21
  • HY-146012
    HIV-1 protease-IN-4 98%
    HIV-1 protease-IN-4 (Compound II-22) is a potent HIV-1 protease inhibitor. HIV-1 protease-IN-4 is a proagent of atazanavir. HIV-1 protease-IN-4 as a proagent that delivers the parent 1 to rat plasma with a 5-fold higher AUC and 67-fold higher C24 when compared to oral administration of the parent agent.
    HIV-1 protease-IN-4
  • HY-146015
    HIV-1 inhibitor-21 2554620-04-9 98%
    HIV-1 inhibitor-21 (compound 9b) is a potent HIV-1 non-nucleoside reverse transcriptase (RT) inhibitor, with an IC50 value of 0.55 μM for HIV-1 RT. HIV-1 inhibitor-21 has antiretroviral activity against HIV-1 WT and K103N strains with EC50s of 12.7 nM and 10.4 nM, and has relatively low cytotoxicity (MT-4 cells CC50 =10.2 μM).
    HIV-1 inhibitor-21
  • HY-146017
    HIV-1 inhibitor-22 2554618-33-4 98%
    HIV-1 inhibitor-22 (compound 11a) is a potent HIV-1 non-nucleoside reverse transcriptase (RT) inhibitor, with an IC50 value of 3.63 μM for HIV-1 RT. HIV-1 inhibitor-22 has antiretroviral activity against HIV-1 WT and K103N strains with EC50s of 0.304 μM and 0.201 μM, also has low cytotoxicity (CC50 > 227 μM)
    HIV-1 inhibitor-22
  • HY-146018
    HIV-1 inhibitor-23 2554622-28-3 98%
    HIV-1 inhibitor-23 (compound 12a) is a highly potent HIV-1 non-nucleoside reverse transcriptase inhibitor, with EC50s of 24.9 nM and 10.4 nM for HIV-1 WT and HIV-1 K103N, respectively. HIV-1 inhibitor-23 has low cytotoxicity (CC50 > 221 μM) and a favorable in vitro microsomal stability.
    HIV-1 inhibitor-23
Cat. No. Product Name / Synonyms Application Reactivity